Acacia Pharma Group plc
Share · GB00BYWF9Y76 (XBRU)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Acacia Pharma Group plc
No Price
Company Profile for Acacia Pharma Group plc Share
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.
Company Data
Name Acacia Pharma Group plc
Company Acacia Pharma Group plc
Website
https://www.acaciapharma.com
Primary Exchange 
EURONEXT - EURONEXT BRUSSELS
EURONEXT - EURONEXT BRUSSELS
ISIN GB00BYWF9Y76
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Michael Bolinder
Country United Kingdom
Currency EUR
Employees 0,1 T
Address The Officers Mess Business Centre, Royston Road, CB22 4QH Cambridge
IPO Date 2018-03-05
Ticker Symbols
| Name | Symbol |
|---|---|
| EURONEXT - EURONEXT BRUSSELS | ACPH.BR |
More Shares
Investors who hold Acacia Pharma Group plc also have the following shares in their portfolio:
